Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Escitalopram Augmentation of Risperidone and Olanzapine in Treatment Resistant Schizophrenia: a Double Blind Placebo Controlled Pilot Study

NCT00231335 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT00231335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00231335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Escitalopram Augmentation of Risperidone and Olanzapine in Treatment Resistant Schizophrenia: a Double Blind Placebo Controlled Pilot Study
Lead sponsor
Emory University
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2006
Completion date
July 31, 2007
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia